NCT07029945 is a Phase 1, PHASE2 clinical trial of BRX011 in Geographic Atrophy, sponsored by Biojiva LLC.

Who is sponsoring NCT07029945?

NCT07029945 is sponsored by Biojiva LLC.

What drugs are being tested in NCT07029945?

Interventions in NCT07029945: BRX011, Placebo.

What condition does NCT07029945 study?

NCT07029945 studies Geographic Atrophy.

Is NCT07029945 still recruiting?

NCT07029945 is currently not yet recruiting. Last updated 26 June 2025.

Last reviewed 2025-06-26 · How we verify

NCT07029945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Not yet recruiting Phase 1, PHASE2 Last updated 26 June 2025

What this trial tests

Phase 1, PHASE2 trial testing BRX011 in Geographic Atrophy in 152 participants. Not yet recruiting.

Timeline

7 July 2025

Primary endpoint
11 November 2026

11 February 2027

Quick facts

Lead sponsor	Biojiva LLC
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	152
Start date	7 July 2025
Primary completion	11 November 2026
Estimated completion	11 February 2027

Drugs / interventions tested

BRX011 — full drug profile →
Placebo

Conditions studied

Geographic Atrophy — all drugs for Geographic Atrophy →

Sponsor

Biojiva LLC — full company profile →

Who can join

55 and older, any sex, with Geographic Atrophy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the safety and efficacy of BRX011, an oral medication, taken once daily by participants with geographic atrophy secondary to age-related macular degeneration. The study is conducted in phases 1 and 2, focusing on assessing both safety (tolerability) and effectiveness (efficacy) of the treatment. Participants: Adults with geographic atrophy due to age-related macular degeneration. Treatment: BRX011 or Placebo is taken once daily as per the protocol. Duration: The study involves multiple visits over 96 weeks to monitor participants' health and response to treatment. Safety Monitoring: Regular checks for adverse events and health status to ensure participant well-being. Checks will include examination of vital signs, clinical labs, ocular exams, and ocular imaging. Primary Outcome Measure: Efficacy of BRX011 in the annual rate of change in the square root of GA area, as specified in the protocol.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Oral Deuterated Docosahexaenoic Acid Protects Against Onset and Progression of RPE Degeneration in a Mouse Model of Chronic Oxidative Stress.
Foshe S, Anderson BD, Song Y, Shi S, et al · · 2026 · PMID 41979253 · DOI 10.1167/iovs.67.4.28

Verify or expand the search:

Other recruiting trials for Geographic Atrophy

Currently open trials in the same condition.

NCT07215234 — A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Se · Phase 1, PHASE2 · recruiting
NCT06961370 — A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO76693 · Phase 1 · recruiting
NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
NCT06769048 — A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) C · Phase 2 · active not recruiting
NCT06805474 — A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT · recruiting

Other Biojiva LLC trials

Trials by the same sponsor.

NCT04937530 — RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY · Phase 2 · unknown
NCT04762589 — RT001 in Amyotrophic Lateral Sclerosis · Phase 2 · completed
NCT04102501 — A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia · Phase 3 · completed
NCT04027816 — A Natural History Study of Infantile Neuroaxonal Dystrophy · completed
NCT03570931 — A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07029945 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biojiva LLC
Last refreshed: 26 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07029945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing